US.BMY · Bristol Myers Squibb

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.1452166802943586,
        "turnoverUsdM": 883.6683767999999,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BMY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 58.5264,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.3,
      "take_profit_price": 64.224,
      "target_multiplier": 1.9,
      "technical_strength": 1.85,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.290433360588717,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 58.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 46.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 12
  },
  "market": {
    "ma20": 64.862,
    "ma50": 64.251,
    "close": 61.15,
    "prevClose": 62.25,
    "avgVolume20": 9803644,
    "volumeRatio": 1.47,
    "changePercent": -1.77
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 12,
    "details": {
      "ret_5d": -0.03852201257861643,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 12,
      "vcp_bonus": 0,
      "vol_ratio": 1.5248837922104883,
      "ret_points": 0,
      "vol_points": 6,
      "range_ratio": 1.4537986451714595,
      "volat_points": 2,
      "day_range_pct": 0.025756320523303323,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 58.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 80,
        "contribution": 4
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 13.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 44.33,
        "contribution": 13.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 46.1,
    "details": [
      "基本面分析總分: 4/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 13.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4,
      "資金流": 5.2,
      "市場環境": 10.2,
      "情緒分析": 4,
      "技術信號": 13.3,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.6,
          "turnoverUsdM": 883.6683767999999,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BMY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.21
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 718.2184960000001,
                "ma50": 711.4151976999997,
                "name": "QQQ",
                "close": 741.21002,
                "points": 2
              },
              "spy": {
                "ma20": 765.28299795,
                "ma50": 760.9057979799998,
                "name": "SPY",
                "close": 767.81,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.1452166802943586,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142314895,
                "url": "https://finnhub.io/api/news?id=5623f852d024055cb2d32412012583ba5ea052c3a4adde817ae8a074a9516832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.",
                "category": "company",
                "datetime": 1790006100,
                "headline": "BMY vs GILD: Which Biotech Stock Looks More Attractive Now?"
              },
              {
                "id": 142259871,
                "url": "https://finnhub.io/api/news?id=6bbc171aa455a9e1cef393f7a806b4de55ca405c14ce345d938a28435af1d8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY vs. ARGX: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1789746003,
                "headline": "BMY vs. ARGX: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142259865,
                "url": "https://finnhub.io/api/news?id=c85c78155c35c9476071a5401ccec9b5080220d6d78f32055ea44c6cd90d9619",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1789738803,
                "headline": "Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?"
              },
              {
                "id": 142255949,
                "url": "https://finnhub.io/api/news?id=93ec90dfede7f478b0d7f075fc193016da74ac9d5c0dfa9a5d9897c3652d36dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1789738802,
                "headline": "Are Medical Stocks Lagging  Bristol Myers Squibb (BMY) This Year?"
              },
              {
                "id": 142253892,
                "url": "https://finnhub.io/api/news?id=2383548f596f69f4a503d7e46afb7df4c49f929d2cc9a837cc60f817aeb3c6d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...",
                "category": "company",
                "datetime": 1789733509,
                "headline": "Bristol Myers Squibb (BMY) Funds India Lung Cancer Screening Research Beyond Smoking"
              },
              {
                "id": 142237154,
                "url": "https://finnhub.io/api/news?id=00f0da4bfba7a16ffceadd9447ba8f041c1c1ec0516785ab9fa0a0467e79ca8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...",
                "category": "company",
                "datetime": 1789705949,
                "headline": "Bristol-Myers Squibb (BMY), What Is Behind The Fresh Attention?"
              },
              {
                "id": 142235572,
                "url": "https://finnhub.io/api/news?id=a6a3236a64edd91d27a3207b4cb03470adfa046705fb6c755adf21c8b48afd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.",
                "category": "company",
                "datetime": 1789681507,
                "headline": "Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 142195330,
                "url": "https://finnhub.io/api/news?id=53d2f4fe4e31987036b337e42ae67b2542f860cb4767dfdb3770606e8187c157",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1789563603,
                "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know"
              }
            ],
            "raw_source": [
              {
                "id": 142364239,
                "url": "https://finnhub.io/api/news?id=de13b6af78ef60c3cd3755c387247dfa19877801097b46c7cd14e0b496479239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "RUTHERFORD, Calif., September 23, 2026--On Saturday, September 19, 2026, leaders in science, philanthropy, and business, community members, and advocates gathered at the Staglin Family Vineyard in Napa Valley for the 32nd annual One Mind Music Festival, presented by Bank of America and Bristol Myers Squibb. The event welcomed more than 500 guests and raised over $3.6M to advance mental health research and discovery.",
                "category": "company",
                "datetime": 1790190660,
                "headline": "Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray"
              },
              {
                "id": 142363145,
                "url": "https://finnhub.io/api/news?id=5161f374f3deb629630ae40445292e5990c242ecad419df57bade675dd405271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.",
                "category": "company",
                "datetime": 1790183924,
                "headline": "What Is AbbVie No Longer Telling You?"
              },
              {
                "id": 142363146,
                "url": "https://finnhub.io/api/news?id=7c6066d745e16db0599e75e745e060580c3f345bfc520df1443e1cb10391555b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.",
                "category": "company",
                "datetime": 1790181437,
                "headline": "What Is The Best Case For Pfizer Stock?"
              },
              {
                "id": 142362095,
                "url": "https://finnhub.io/api/news?id=6dc633dc3d05ff04cfd2f5260158c2060de38e796581ecf6de15ffca979ee37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The Rare Access Action Project (RAAP) announced today that Bristol Myers Squibb (BMS) has joined RAAP as its newest member, expanding the coalition of patient and life sciences stakeholders working together to address access and coverage challenges affecting people living with rare diseases.",
                "category": "company",
                "datetime": 1790172060,
                "headline": "New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP"
              },
              {
                "id": 142359765,
                "url": "https://finnhub.io/api/news?id=38c72948aee676bd4ba0681639f68635724ebe629a5f3d2bcd644aee7814f9c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
                "category": "company",
                "datetime": 1790169014,
                "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks"
              },
              {
                "id": 142358849,
                "url": "https://finnhub.io/api/news?id=61805feacc3ee6da25ef098b50d7d4d2f0118e17a8074c3a4f616b5d00ed8e68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.",
                "category": "company",
                "datetime": 1790168501,
                "headline": "4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout"
              },
              {
                "id": 142339882,
                "url": "https://finnhub.io/api/news?id=a8962ecbd35b33c0d4877e88033484063f9ae6df0220fbb98d418d294f173f16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.",
                "category": "company",
                "datetime": 1790088464,
                "headline": "Eli Lilly Breaks Ground on $6.5B Generation Park Facility"
              },
              {
                "id": 142339888,
                "url": "https://finnhub.io/api/news?id=521f537e1ccd22d016f77968e273dfe4cdf5c5888d6da300c4de98eb6b88ce02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.",
                "category": "company",
                "datetime": 1790085012,
                "headline": "Could You Have Seen Merck Stock's Pipeline Run Coming?"
              },
              {
                "id": 142337706,
                "url": "https://finnhub.io/api/news?id=93ee11e969216f043a97b637ce8eef0d26325f1151ce7be2c5e31a719763b7b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization",
                "category": "company",
                "datetime": 1790078400,
                "headline": "AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization"
              },
              {
                "id": 142336898,
                "url": "https://finnhub.io/api/news?id=30ade6995bc892c80adbf84f3e46e2fe8e1993bd8512c4acd8de0529b51de6f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 22, 2026 / Originally published on DevexLung cancer remains the leading cause of cancer death worldwide, yet in resource-limited settings, patients face severe barriers to early diagnosis-while TB is regularly identified and treated, signs and indications of lung cancer are often overlooked. Nestory Masalu, Head of Oncology for the Catholic University of Health and Allied Sciences/Bugando Medical Center, explains how his team is dismantling these dia",
                "category": "company",
                "datetime": 1790076540,
                "headline": "Transforming Lung Cancer Care & Early Detection in Tanzania"
              },
              {
                "id": 142315573,
                "url": "https://finnhub.io/api/news?id=e8fac27152be06dd14b7ae6fa396dbcd17df4efc42a02489815d6e9e6e3d0dc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.¹ “Onco360 is grateful for the",
                "category": "company",
                "datetime": 1790024400,
                "headline": "Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network"
              },
              {
                "id": 142314895,
                "url": "https://finnhub.io/api/news?id=5623f852d024055cb2d32412012583ba5ea052c3a4adde817ae8a074a9516832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.",
                "category": "company",
                "datetime": 1790006100,
                "headline": "BMY vs GILD: Which Biotech Stock Looks More Attractive Now?"
              },
              {
                "id": 142314289,
                "url": "https://finnhub.io/api/news?id=43c5b8d478c44c5c601e95e4f5d0e6e83ec991b24d54554113f36b06e5927bc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.",
                "category": "company",
                "datetime": 1790000231,
                "headline": "What Would It Take For Pfizer To Cut Its Dividend?"
              },
              {
                "id": 142287662,
                "url": "https://finnhub.io/api/news?id=755644a8265743a3923e1824ea564b2a7bc3569e184bb005d0dc0c38d6f8be23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.",
                "category": "company",
                "datetime": 1789908600,
                "headline": "Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder"
              },
              {
                "id": 142259738,
                "url": "https://finnhub.io/api/news?id=9213a12cc5d3cd4a1ff83deb1474a34573628ceec6eae490be90b20e07f205ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.",
                "category": "company",
                "datetime": 1789759020,
                "headline": "Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?"
              },
              {
                "id": 142259470,
                "url": "https://finnhub.io/api/news?id=92f987af62e597d433d764b32bc34040d20ff98a77507c00fc79b26e76a00f4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.",
                "category": "company",
                "datetime": 1789754949,
                "headline": "Merck Stock Nearly Doubled Without A Change In Its Revenue Growth"
              },
              {
                "id": 142259871,
                "url": "https://finnhub.io/api/news?id=6bbc171aa455a9e1cef393f7a806b4de55ca405c14ce345d938a28435af1d8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY vs. ARGX: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1789746003,
                "headline": "BMY vs. ARGX: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142259575,
                "url": "https://finnhub.io/api/news?id=41927abf64b55e3d6fa322cce5ffdea667fc15cf1e3377139b330dcaddd04d9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.",
                "category": "company",
                "datetime": 1789744004,
                "headline": "Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?"
              },
              {
                "id": 142270759,
                "url": "https://finnhub.io/api/news?id=1bcf6ee563430cc61db1503eb276ecd833cf68ba518a9c7ab00d8fc848351aea",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/18/Genetic-Research-And-Biotech-Science-Con.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.",
                "category": "company",
                "datetime": 1789739562,
                "headline": "This $3 Biotech Could Be Worth $11.45, Analyst Says"
              },
              {
                "id": 142259865,
                "url": "https://finnhub.io/api/news?id=c85c78155c35c9476071a5401ccec9b5080220d6d78f32055ea44c6cd90d9619",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1789738803,
                "headline": "Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?"
              },
              {
                "id": 142255949,
                "url": "https://finnhub.io/api/news?id=93ec90dfede7f478b0d7f075fc193016da74ac9d5c0dfa9a5d9897c3652d36dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1789738802,
                "headline": "Are Medical Stocks Lagging  Bristol Myers Squibb (BMY) This Year?"
              },
              {
                "id": 142270760,
                "url": "https://finnhub.io/api/news?id=a8243e144bb0c5f7780d839884fdec3451a4733654b7cc2f6f745ff2d11b9ec2",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1789738514,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142259528,
                "url": "https://finnhub.io/api/news?id=3a1e2000579852f3b34752bbd857d32b9504e254c87464c87d497a08838a6184",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.",
                "category": "company",
                "datetime": 1789738501,
                "headline": "AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142253892,
                "url": "https://finnhub.io/api/news?id=2383548f596f69f4a503d7e46afb7df4c49f929d2cc9a837cc60f817aeb3c6d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...",
                "category": "company",
                "datetime": 1789733509,
                "headline": "Bristol Myers Squibb (BMY) Funds India Lung Cancer Screening Research Beyond Smoking"
              },
              {
                "id": 142253118,
                "url": "https://finnhub.io/api/news?id=efd718ae91bddac44569eff8005836a4da11ae0ad4c975e830610eac2254448f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 18, 2026--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026",
                "category": "company",
                "datetime": 1789729140,
                "headline": "Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026"
              },
              {
                "id": 142259868,
                "url": "https://finnhub.io/api/news?id=80246df6ee067f6c4292e7212ddd7e213af8e49d16e2651d0d0f54b0bab16dfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.",
                "category": "company",
                "datetime": 1789727040,
                "headline": "Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug"
              },
              {
                "id": 142254787,
                "url": "https://finnhub.io/api/news?id=9e36abb4736760f20f2560d69abeba3d6a402c6a5b6c3ebfc2d1ef95ab93e692",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630128517/image_1630128517.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.",
                "category": "company",
                "datetime": 1789723352,
                "headline": "5 Undervalued Oncology Stocks Wall Street Is Overlooking"
              },
              {
                "id": 142237154,
                "url": "https://finnhub.io/api/news?id=00f0da4bfba7a16ffceadd9447ba8f041c1c1ec0516785ab9fa0a0467e79ca8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...",
                "category": "company",
                "datetime": 1789705949,
                "headline": "Bristol-Myers Squibb (BMY), What Is Behind The Fresh Attention?"
              },
              {
                "id": 142235572,
                "url": "https://finnhub.io/api/news?id=a6a3236a64edd91d27a3207b4cb03470adfa046705fb6c755adf21c8b48afd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.",
                "category": "company",
                "datetime": 1789681507,
                "headline": "Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 142235573,
                "url": "https://finnhub.io/api/news?id=42e94daa97320ae44857d9495f0356dfa8f3209000b8e3920dce3742941c7a57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
                "category": "company",
                "datetime": 1789650601,
                "headline": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks"
              },
              {
                "id": 142223863,
                "url": "https://finnhub.io/api/news?id=dc4cbf8b69fbadfb93aa4d383979cd3fcb3a5cf28f9596c1e165bded9540a7e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.",
                "category": "company",
                "datetime": 1789647089,
                "headline": "What Happens To AbbVie Stock If SKYRIZI Slows Down?"
              },
              {
                "id": 142255455,
                "url": "https://finnhub.io/api/news?id=c9038077b8187e50e783ad351b4d6611f9a5f066bbb63eb7dace4fd29a2e929d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/17/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.",
                "category": "company",
                "datetime": 1789645556,
                "headline": "Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years"
              },
              {
                "id": 142224113,
                "url": "https://finnhub.io/api/news?id=61d101b15444a8ecc402a35ccfda0b8b060f1929b4f9cb3e1063022e0924f043",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Opinion: Current lung cancer screening policy leaves gaps around air pollution, exposure, and genetics. Two new trials in India are creating the localized evidence needed to build a screening policy tailored to a true at-risk profile.",
                "category": "company",
                "datetime": 1789644540,
                "headline": "How Can Lung Cancer Screening in India Reflect Risk Beyond Smoking?"
              },
              {
                "id": 142224114,
                "url": "https://finnhub.io/api/news?id=38df04f79fb042ccfb355646c3e0842c81ac03be563f97b669b5d358f4c6c102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 17, 2026--Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years",
                "category": "company",
                "datetime": 1789642740,
                "headline": "Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years"
              },
              {
                "id": 142225043,
                "url": "https://finnhub.io/api/news?id=b04508b591221a75400653d6735ee0d63623deb4399348c46df74a250652f622",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1661126796/image_1661126796.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.",
                "category": "company",
                "datetime": 1789637571,
                "headline": "Summit Therapeutics: It's Okay Not To Have An Answer"
              },
              {
                "id": 142225502,
                "url": "https://finnhub.io/api/news?id=9a283e5d2d64c3fdec9966d719a036e9b70a41a2b50a40fdb8f0e980ff94753e",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California, taking place September 17-20, 2026.Among patients who entered the OLE, Sotyktu demonstrated",
                "category": "company",
                "datetime": 1789629140,
                "headline": "Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu"
              },
              {
                "id": 142201180,
                "url": "https://finnhub.io/api/news?id=f18ff60a19b03a3e4eb745f510ed74b65c961a3130cc840808d3eb4280fba88d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.",
                "category": "company",
                "datetime": 1789589528,
                "headline": "Is Pfizer's New Business Big Enough To Carry The Old One?"
              },
              {
                "id": 142197199,
                "url": "https://finnhub.io/api/news?id=41f744ffe12c1d0fcc3f5d7575837d773a5bc2c3805482ee5a0ef6a9e39ae877",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...",
                "category": "company",
                "datetime": 1789569420,
                "headline": "AstraZeneca shares oversold after trial flops and merger talk, says UBS"
              },
              {
                "id": 142225503,
                "url": "https://finnhub.io/api/news?id=732cfb98c41e19f58bbfd6d56889b4b3a1320ee616a54ef5529bbc4fe9580138",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Piper Sandler  analyst David Amsellem   reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.",
                "category": "company",
                "datetime": 1789565087,
                "headline": "Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82"
              },
              {
                "id": 142195330,
                "url": "https://finnhub.io/api/news?id=53d2f4fe4e31987036b337e42ae67b2542f860cb4767dfdb3770606e8187c157",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1789563603,
                "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142193934,
                "url": "https://finnhub.io/api/news?id=8afdb50e2d2b4a946037454091ddceb6e660a8a264b756fbc8025bc187a02a27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 16, 2026--Bristol Myers Squibb Announces Dividend",
                "category": "company",
                "datetime": 1789556340,
                "headline": "Bristol Myers Squibb Announces Dividend"
              },
              {
                "id": 142172297,
                "url": "https://finnhub.io/api/news?id=bd676c4b44a7da2d7f11725925ca1f235568cd8910e075fe2bc5a17b09e1dee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.",
                "category": "company",
                "datetime": 1789519473,
                "headline": "Merck Stock: Is The $70 Billion Pipeline Worth the Premium?"
              },
              {
                "id": 142165474,
                "url": "https://finnhub.io/api/news?id=44f390931c8b2233b15db8409363a143ac90c99313d731cdc169152eeabf6adc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "RDW turns microgravity into a commercial platform, spanning pharmaceutical research, biotechnology and advanced manufacturing.",
                "category": "company",
                "datetime": 1789482840,
                "headline": "Can Redwire's Microgravity Platform Expand Commercial Opportunities?"
              },
              {
                "id": 142160454,
                "url": "https://finnhub.io/api/news?id=dae1ac830485caf254f2c972f31e7da575595246c47381b6599f2a025c516b72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "In early September 2026, Bristol Myers Squibb reported positive Phase 2 results from its registrational QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel), a potential first-in-class GPRC5D-directed CAR T cell therapy for heavily pretreated adults with relapsed and refractory multiple myeloma, meeting its primary and key secondary response endpoints with a safety profile in line with existing CAR T treatments. The data are particularly important because arlo-cel targets GPRC5D...",
                "category": "company",
                "datetime": 1789470949,
                "headline": "The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Arlo-cel’s Positive Phase 2 Myeloma Data"
              },
              {
                "id": 142141406,
                "url": "https://finnhub.io/api/news?id=e37148134b2f7452c0ceaaf02e895b7442ec37c6357e70dadd2e0a83cc3eb9db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.",
                "category": "company",
                "datetime": 1789415853,
                "headline": "Why Is Pfizer Stock Paying You So Much To Wait?"
              },
              {
                "id": 142139504,
                "url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
                "category": "company",
                "datetime": 1789399410,
                "headline": "3 Healthcare Stocks That Fall Short"
              },
              {
                "id": 142139505,
                "url": "https://finnhub.io/api/news?id=413c61a2867e3ffce712e9332c0dcdac3bd3793a2a001dc9c92dcd3735072358",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "DelveInsight's Bispecifics Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythema",
                "category": "company",
                "datetime": 1789396260,
                "headline": "Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight"
              },
              {
                "id": 142137177,
                "url": "https://finnhub.io/api/news?id=7bc4aea4ec95b56bd0f34332108b1457a014059262be4c7e516885fac8e0c08f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.",
                "category": "company",
                "datetime": 1789391100,
                "headline": "BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors"
              },
              {
                "id": 142136806,
                "url": "https://finnhub.io/api/news?id=35514cfc0bcb0511bc31265505def0b96051a8ae83a46bbdafce91ac25c795f2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/728909377/image_728909377.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Cytokinetics, Incorporated stock faces pressure as Myqorzo sales jump 427% and NEJM Phase 3 data show efficacy vs. Camzyos—plus LVEF risk. Click for more on CYTK stock.",
                "category": "company",
                "datetime": 1789376855,
                "headline": "Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet"
              },
              {
                "id": 142133911,
                "url": "https://finnhub.io/api/news?id=081b98b5d25d6f244f391b421ddfad7d2c7255d5eed2d29386b3ce5fa4b198da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.",
                "category": "company",
                "datetime": 1789372740,
                "headline": "Big Pharma Is Pouring Billions Into China’s Biotechs"
              },
              {
                "id": 142125067,
                "url": "https://finnhub.io/api/news?id=7e26736d400522145fd61c3724face31c42ea55559cd83350c84890cbeba6b18",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.",
                "category": "company",
                "datetime": 1789329180,
                "headline": "Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?"
              },
              {
                "id": 142116372,
                "url": "https://finnhub.io/api/news?id=cea9aaf58596f64bae99b04269e5e394d1003c5d9577c95ffc05370553a25261",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Collecting $10,000 a year from Bristol Myers Squibb sounds straightforward until you factor in a looming patent cliff that threatens the very earnings funding that payout. Here is what the math and the risk actually look like together.",
                "category": "company",
                "datetime": 1789240537,
                "headline": "How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?"
              },
              {
                "id": 142089433,
                "url": "https://finnhub.io/api/news?id=4ae9498ecd56e299779ddffb0f6ac4ad216aa14954b49be19d26f04673465af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.",
                "category": "company",
                "datetime": 1789153872,
                "headline": "Is AbbVie Stock Actually Overpriced?"
              },
              {
                "id": 142087095,
                "url": "https://finnhub.io/api/news?id=3f68237b52bc07ee41445a0243eb8e461258e10ef1e9fda3f64a0a23ece2ee75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.",
                "category": "company",
                "datetime": 1789139820,
                "headline": "MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE"
              },
              {
                "id": 142087192,
                "url": "https://finnhub.io/api/news?id=31c0e6117f1ad766e1277bf2e6484afaa811c575359894244ddfa808c5e07296",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments. The therapy produced a statistically significant and clinically meaningful improvement in overall response rates. It also met […]",
                "category": "company",
                "datetime": 1789139802,
                "headline": "Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline"
              },
              {
                "id": 142066251,
                "url": "https://finnhub.io/api/news?id=f821a4097c81405b928122f9b8ec1467191361a9e6a725676fdfae39bd714889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.",
                "category": "company",
                "datetime": 1789076702,
                "headline": "Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 142064839,
                "url": "https://finnhub.io/api/news?id=d3e1c3d021cac8d7c584fceec4a97330718f45fbfe390ee1bceaaa151e813902",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.",
                "category": "company",
                "datetime": 1789065600,
                "headline": "Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More."
              },
              {
                "id": 142063381,
                "url": "https://finnhub.io/api/news?id=6e01b05c59628b4ff2dcc86605fe7a7840361eb6b84e1b205c557234aad4d152",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.",
                "category": "company",
                "datetime": 1789062420,
                "headline": "BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142063382,
                "url": "https://finnhub.io/api/news?id=6b21a9385e4c2991811576acb36fe32a9b4bd405028d1ef55b707b5ed008ab11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.",
                "category": "company",
                "datetime": 1789060440,
                "headline": "‘Miracle’ Cancer Drug Sets Revolution Medicines Up for More Market Share Gains"
              },
              {
                "id": 142063383,
                "url": "https://finnhub.io/api/news?id=975cba2017d69c30ce859b2ba3e14a66488b8b0beb50da26f10f6b5b7a22f260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY)",
                "category": "company",
                "datetime": 1789056517,
                "headline": "Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061864,
                "url": "https://finnhub.io/api/news?id=c282b2ed87af4f65da96e620cab13fb3fbb35e9922e8ba386e2f724c8e629d02",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.",
                "category": "company",
                "datetime": 1789034353,
                "headline": "HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65"
              },
              {
                "id": 142050448,
                "url": "https://finnhub.io/api/news?id=3bd4334d3c508539047fb6dc644fa4509be3b787e95bb21bb331eefd2d3bb170",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY clears ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but high payout and falling earnings raise sustainability concerns.",
                "category": "company",
                "datetime": 1789030256,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142029881,
                "url": "https://finnhub.io/api/news?id=6e7355750110ec6cc714f5fd02f23dde4c593ccf21d981b2a31b4ed52e5a5871",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]",
                "category": "company",
                "datetime": 1788989678,
                "headline": "Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?"
              },
              {
                "id": 142026021,
                "url": "https://finnhub.io/api/news?id=8594abe1497fc9106ab538c18da2afa5b36087b9d3b0a4028a4f1f1878bc3195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.",
                "category": "company",
                "datetime": 1788966840,
                "headline": "Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?"
              },
              {
                "id": 142024726,
                "url": "https://finnhub.io/api/news?id=c0d76a8928e2fd50eb24afaead652811d0bc0a50082e531baea6c1e64d4b6a32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.",
                "category": "company",
                "datetime": 1788955235,
                "headline": "IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?"
              },
              {
                "id": 142024029,
                "url": "https://finnhub.io/api/news?id=5d724dc0d23a3ebfb1bd6d0a5bbc3f6abe35c00597154f556bba279682e3f9e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For AllPreviously published by the Robert A. Winn Excellence in Clinical Trials Award ProgramA growing coalition of pharmaceutical companies, nonprofit organizations, academic institutions, and clinical research leaders came together through the Robert A.",
                "category": "company",
                "datetime": 1788953340,
                "headline": "National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort"
              },
              {
                "id": 142024031,
                "url": "https://finnhub.io/api/news?id=063037dddb1b85bf3368a02f66a8d588d9c9fa8107f047a9bdc33e346d35cc7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PHILADELPHIA & BOSTON, September 09, 2026--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medi",
                "category": "company",
                "datetime": 1788951600,
                "headline": "Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair"
              },
              {
                "id": 142006735,
                "url": "https://finnhub.io/api/news?id=93f43e8d7a6488047bd97f1f3f5b6b0aace302de3570d756adf3cb3977279639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Potential extends to earlier-line use, injection-averse patients and new immune-mediated indicationsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The \"SOTYKTU Sales Forecast, and Market Size Analysis - 2034\" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France,",
                "category": "company",
                "datetime": 1788947400,
                "headline": "SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026"
              },
              {
                "id": 141989983,
                "url": "https://finnhub.io/api/news?id=7d0d0a2d383ecb4b94b6d473fd49c6fbe2070ce7fc93b814f798c45ea4a25353",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "CD&R (or the \"Firm\") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.",
                "category": "company",
                "datetime": 1788940800,
                "headline": "Giovanni Caforio Appointed Operating Advisor to CD&R Funds"
              },
              {
                "id": 142023862,
                "url": "https://finnhub.io/api/news?id=11fd80725570f8c725693b9b19b81a17ee99e6102f0085df9eb27e7c4d33d9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.",
                "category": "company",
                "datetime": 1788937200,
                "headline": "A new immuno-oncology play raises $225M for a next-generation drug"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141950403,
                "url": "https://finnhub.io/api/news?id=de977806d1f6a3f5226aacf507ea60491cd0a478de36e23fee0a088aa2fcf14b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.",
                "category": "company",
                "datetime": 1788880260,
                "headline": "Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends"
              },
              {
                "id": 141955168,
                "url": "https://finnhub.io/api/news?id=354a3a64457ffc02565ac5874663d068bf8ae6d0dab0736fef80a2cab40b1ea1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.",
                "category": "company",
                "datetime": 1788878460,
                "headline": "Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141950417,
                "url": "https://finnhub.io/api/news?id=4da9cb88add93435fb30761985c61678f15bf041a6bc9c6ec7cfba6482d7db78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and some have raised their payouts for decades straight.",
                "category": "company",
                "datetime": 1788870027,
                "headline": "Social Security’s 2027 COLA Raise Is the Biggest in 3 Years — But These 5 Dividend Stocks Pay You More"
              },
              {
                "id": 141956122,
                "url": "https://finnhub.io/api/news?id=97dd77234af9ebb51eeba22fdd986eb8f5c878fed4ab2d63990cdaa1e8fde2c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.",
                "category": "company",
                "datetime": 1788866019,
                "headline": "Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients"
              },
              {
                "id": 141950637,
                "url": "https://finnhub.io/api/news?id=731b6c5e68dd8aeb91caf2ed17644c56ecf1e42a7a9706b26ce396bbc55fe995",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 08, 2026--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial",
                "category": "company",
                "datetime": 1788865140,
                "headline": "Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..."
              },
              {
                "id": 141956123,
                "url": "https://finnhub.io/api/news?id=96a5b74caea66006e472c651805034579ac56ae3ad200ada8a95836edfbd2691",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapyQUINTESSENTIAL",
                "category": "company",
                "datetime": 1788850908,
                "headline": "Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate"
              },
              {
                "id": 141771129,
                "url": "https://finnhub.io/api/news?id=8d4ddd4505d0a2c0a565fc6aa50cad54667e4793873643445d02cbd7344ed953",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.",
                "category": "company",
                "datetime": 1788800445,
                "headline": "Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now"
              },
              {
                "id": 141588073,
                "url": "https://finnhub.io/api/news?id=48b74053277caa2f5fc954cf5a1549051ca2d8f182c010e0532f07651e937caf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]",
                "category": "company",
                "datetime": 1788691442,
                "headline": "Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real"
              },
              {
                "id": 141510752,
                "url": "https://finnhub.io/api/news?id=8f773fba44f0e7544ca2cbb54343407ebab89f7232589267dad714a725175f2e",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.",
                "category": "company",
                "datetime": 1788604391,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup"
              },
              {
                "id": 141519412,
                "url": "https://finnhub.io/api/news?id=6af93749a5ad16862681beb37392c6dbbeea357e33f9580e3c70c35e1ac295aa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/639990738/image_639990738.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.",
                "category": "company",
                "datetime": 1788600504,
                "headline": "Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum"
              },
              {
                "id": 141464650,
                "url": "https://finnhub.io/api/news?id=70bb4c3c9e836a39e3653498cfd536deac69a7e1b0f43a4312691060ad284681",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788558303,
                "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today"
              },
              {
                "id": 141455206,
                "url": "https://finnhub.io/api/news?id=46008aa3897fb677a8af52c36fef7934feeddbea4974aa4a9324d40d2d3fa952",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and",
                "category": "company",
                "datetime": 1788551323,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 141446802,
                "url": "https://finnhub.io/api/news?id=c0f942183fae38ee06ed79bbe8fc8646f128780b439a91f430d200e429947d94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H",
                "category": "company",
                "datetime": 1788543665,
                "headline": "Sector Update: Healthcare Stocks Decline Friday Afternoon"
              },
              {
                "id": 141449962,
                "url": "https://finnhub.io/api/news?id=d153250c15bd81ad13b67c1c078e93d454b22ba333de2be0cd15c2ad6f3c0dd9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/04/Gene-Therapy-For-Cancer-Treatment-Concep.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.",
                "category": "company",
                "datetime": 1788521599,
                "headline": "A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths"
              },
              {
                "id": 141425668,
                "url": "https://finnhub.io/api/news?id=47c4b2ed2bec38e175d04009665aa290eda845b05591564bb0fb1d56c72fc776",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it",
                "category": "company",
                "datetime": 1788516629,
                "headline": "Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns"
              },
              {
                "id": 141428557,
                "url": "https://finnhub.io/api/news?id=2c936dd7ab91688beb9ce6da968db548fae82c3c793c1a2644cb30d80a20c6c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2235602110/image_2235602110.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) stock: Strong Buy at 51% sector discount.",
                "category": "company",
                "datetime": 1788514558,
                "headline": "Bristol Myers Squibb: Still Cheap, Despite What The Chart Says"
              },
              {
                "id": 141419536,
                "url": "https://finnhub.io/api/news?id=a2942230b861cfeb31ee86052445c0ff49d003fd707bfd6531e98eba172a935a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2263099480/image_2263099480.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.",
                "category": "company",
                "datetime": 1788506143,
                "headline": "Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401623,
                "url": "https://finnhub.io/api/news?id=571938922c53a24695a79bd4b7bcf6cadc277e382964d905e6dd29c162da8113",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.",
                "category": "company",
                "datetime": 1788454800,
                "headline": "Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141405350,
                "url": "https://finnhub.io/api/news?id=de1594f724537536ca19ee63ebf071fe4fc45ec11574bf34e50fd61d28fcead4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1788449992,
                "headline": "Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?"
              },
              {
                "id": 141400446,
                "url": "https://finnhub.io/api/news?id=cdbc5a2b8ff74d546c660d56825b641d1ba0c356cd2404e5938aade463184630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449413,
                "headline": "Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?"
              },
              {
                "id": 141398201,
                "url": "https://finnhub.io/api/news?id=7a9b4dba5bb25cb824438647b9a5d247c34500fcf42d1f57a257b2902488f1d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.",
                "category": "company",
                "datetime": 1788444000,
                "headline": "Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds"
              },
              {
                "id": 141397416,
                "url": "https://finnhub.io/api/news?id=df0f1022286d048bdd9a82a3e3011888ddbb9f5c783b06f8b7ec5d74057d1fd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicin",
                "category": "company",
                "datetime": 1788435000,
                "headline": "Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer"
              },
              {
                "id": 141396046,
                "url": "https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Reviewing prior stock picks is how investors turn experience into valuable feedback.  A recommendation is only a thesis until the market tests it.  Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.",
                "category": "company",
                "datetime": 1788414660,
                "headline": "Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"
              },
              {
                "id": 141395435,
                "url": "https://finnhub.io/api/news?id=3020ee035c6b5fa5f63c33a9349fbac264d79c0593069f9eb52783c81993f5b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...",
                "category": "company",
                "datetime": 1788409879,
                "headline": "What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141379847,
                "url": "https://finnhub.io/api/news?id=79f18174ad181fad00cc082df546211492fa49c31b6547541fd791f75251ab3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.",
                "category": "company",
                "datetime": 1788377400,
                "headline": "Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?"
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379845,
                "url": "https://finnhub.io/api/news?id=9857fac7df0ba122b7ab45bf81308ca0b990fbf4f3d6509b48b838ae64cba442",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...",
                "category": "company",
                "datetime": 1788365223,
                "headline": "Bristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?"
              },
              {
                "id": 141379150,
                "url": "https://finnhub.io/api/news?id=fac6b53077cb17d7af20e819aacca07cf62593653b986be157b110f4bed8e7fd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1788356125,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141379846,
                "url": "https://finnhub.io/api/news?id=afe4f9f5def2846b7cd3e3eed0ea60466a12b33633dc1dbf6d41f78c22339a78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.",
                "category": "company",
                "datetime": 1788355920,
                "headline": "Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts"
              },
              {
                "id": 141376781,
                "url": "https://finnhub.io/api/news?id=3ee7793f113eb640bae9719676ac3ff7bda91affcde9e0a3c17a72bab4ca4c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...",
                "category": "company",
                "datetime": 1788354000,
                "headline": "Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials"
              },
              {
                "id": 141375563,
                "url": "https://finnhub.io/api/news?id=7ab5bcd12588ce30f4b5b5a311969bf31606f4bc2cce08218a7a22084c60a831",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.",
                "category": "company",
                "datetime": 1788334184,
                "headline": "Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half"
              },
              {
                "id": 141373338,
                "url": "https://finnhub.io/api/news?id=1d85fa178dacb2e1c48eded9517b42e4492e5fea195b64e93350dbc027ef2ca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Bristol-Myers Squibb (NYSE:BMY).",
                "category": "company",
                "datetime": 1788294140,
                "headline": "Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest"
              },
              {
                "id": 141369876,
                "url": "https://finnhub.io/api/news?id=b4b729cd08099e1154aab3a209d040b8a59a911ae8a6cb3d1379f2bf2e6d31aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788288240,
                "headline": "Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023."
              },
              {
                "id": 141369812,
                "url": "https://finnhub.io/api/news?id=ebd7a8f25257402a2a2fed29a89696330649006797da39c623f94590dbe226b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.",
                "category": "company",
                "datetime": 1788286200,
                "headline": "Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal"
              },
              {
                "id": 141371042,
                "url": "https://finnhub.io/api/news?id=c3d97f2474ba1492f45d4aefcbd682b0faccc912990f1b6b655e1715fbc06cb6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282553745/image_2282553745.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.",
                "category": "company",
                "datetime": 1788280574,
                "headline": "Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside"
              },
              {
                "id": 141369873,
                "url": "https://finnhub.io/api/news?id=1bce6207890c6536b7e9eb485b632e6b759d6d03e2e31443e056c8d59c8c4270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.",
                "category": "company",
                "datetime": 1788276420,
                "headline": "Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough"
              },
              {
                "id": 141360820,
                "url": "https://finnhub.io/api/news?id=1df0df20de7aabb85df09fc4c34c5731bfc6fe40781bd266d3afd73797d03fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.",
                "category": "company",
                "datetime": 1788202928,
                "headline": "This Popular Healthcare ETF Is Diluting Your Dividend Income"
              },
              {
                "id": 141362139,
                "url": "https://finnhub.io/api/news?id=334ff16fb2f1413e92ef1f691bbdf3a5ee9ba6dfa0ecafb773f753b6ca7f91c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects led Bristol Myers to voluntarily pause its zola-cel program.",
                "category": "company",
                "datetime": 1788201480,
                "headline": "Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns"
              },
              {
                "id": 141362143,
                "url": "https://finnhub.io/api/news?id=9ca2dc520325e202435daf86c34b88f8aeb4b6ba8a8c1f3c7cef6e595b299374",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return during that period. This might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1788198864,
                "headline": "3 Reasons to Sell BMY and 1 Stock to Buy Instead"
              },
              {
                "id": 141361469,
                "url": "https://finnhub.io/api/news?id=34e30cd031c810d63415f91661c6455830424a81e544234aa232e3fa4a773e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788194343,
                "headline": "Cocrystal Pharma: The Strategic Reset Investors May Be Missing"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141362140,
                "url": "https://finnhub.io/api/news?id=e97b2a46f32c37f55844c94c141bf555c1e96bec9907648b43645032263930ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.",
                "category": "company",
                "datetime": 1788177619,
                "headline": "Jefferies starts biopharma firm Braveheart at Buy after IPO"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141355665,
                "url": "https://finnhub.io/api/news?id=3fb9e5cd83d56af0ff3106385f22de9c49bf39ee4ed9345011f08565e400441a",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in",
                "category": "company",
                "datetime": 1788147649,
                "headline": "Reported Earlier, Bristol Myers Reports Long-Term Camzyos Data Supporting Continued Use In Obstructive HCM"
              },
              {
                "id": 141362133,
                "url": "https://finnhub.io/api/news?id=436efdcbe711a0f6ddfca43b40c1dad10ef68eec29760201884503af8b82c8bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., August 29, 2026--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten)....",
                "category": "company",
                "datetime": 1788019200,
                "headline": "Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026"
              },
              {
                "id": 141351859,
                "url": "https://finnhub.io/api/news?id=7f55208ed921c5798e709369aaccb858071caf982e8dd81a39c805fca5c5aee7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.",
                "category": "company",
                "datetime": 1788017700,
                "headline": "Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors"
              },
              {
                "id": 141362144,
                "url": "https://finnhub.io/api/news?id=55df3c57fa9890a965add1d96a939aeca371acf539b8f1539877ff7205fd8e49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb has delivered a strong 47.9% return over the past year, yet several valuation checks still frame the stock as cheap relative to an intrinsic value estimate and to market multiples. For investors, the question is whether the current share price reflects a genuine discount or simply the market catching up with earlier pessimism. The 47.9% gain over 1 year highlights how sharply sentiment toward Bristol-Myers Squibb has improved. This can reduce the margin of safety if...",
                "category": "company",
                "datetime": 1788005206,
                "headline": "Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value"
              },
              {
                "id": 141348567,
                "url": "https://finnhub.io/api/news?id=a379190190bdec036257d2748e072424c5c1b755ec036e7bddcd9936dbdcf104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]",
                "category": "company",
                "datetime": 1787974085,
                "headline": "Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb"
              },
              {
                "id": 141362141,
                "url": "https://finnhub.io/api/news?id=d3a233ad9f5bb28e9b5a10b466b1edba3ad286f94aa15528621c639e8403ff1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.",
                "category": "company",
                "datetime": 1787951157,
                "headline": "Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop"
              },
              {
                "id": 141362136,
                "url": "https://finnhub.io/api/news?id=d9056e80fd9cbb58555a4a0f29cbfc2ca1c6dc2c00c4fd7e960960cc760e728f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]",
                "category": "company",
                "datetime": 1787949764,
                "headline": "Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?"
              },
              {
                "id": 141348570,
                "url": "https://finnhub.io/api/news?id=4f0e161ba9b9cba902841c73156b0682cae4aa772893993f336979cf573e608d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.",
                "category": "company",
                "datetime": 1787945738,
                "headline": "Can Merck Stock Outrun Its Pipeline?"
              },
              {
                "id": 141339624,
                "url": "https://finnhub.io/api/news?id=44cf81c569d9ca518128cd7ce1b63abb0cdaab2e4a4b7891731afcb9cd738ed8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2291247270/image_2291247270.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.",
                "category": "company",
                "datetime": 1787933252,
                "headline": "BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More"
              },
              {
                "id": 141362146,
                "url": "https://finnhub.io/api/news?id=1080e54369b4b31bc32dce6d9863d09688d4c17938b85d8187eaec3f63d7d55a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1787921092,
                "headline": "1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges"
              },
              {
                "id": 141362137,
                "url": "https://finnhub.io/api/news?id=6ee8eadf9d92b1904e53af83a55f01493b8a6601d1ba9c95910d273b180cb33d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]",
                "category": "company",
                "datetime": 1787880998,
                "headline": "Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth"
              },
              {
                "id": 141348581,
                "url": "https://finnhub.io/api/news?id=24458578ebb7cce18a55c1f2c5cdd3519fc2d2bc100626b8dba0bb612a1376ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]",
                "category": "company",
                "datetime": 1787879505,
                "headline": "New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst"
              },
              {
                "id": 141360948,
                "url": "https://finnhub.io/api/news?id=d996d90295ae96f1cb973a3c6604fa866b3ac5806908170eba6410dd94f3ffe8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.",
                "category": "company",
                "datetime": 1787853707,
                "headline": "Is Merck Stock Reaching A Valuation Ceiling At 6x Sales?"
              },
              {
                "id": 141362149,
                "url": "https://finnhub.io/api/news?id=90f49ef3b7673d7f949bab1cdfe3043d3fe35edbc1810fdcd7e4306777a6bb64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.",
                "category": "company",
                "datetime": 1787853600,
                "headline": "RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer"
              },
              {
                "id": 141362150,
                "url": "https://finnhub.io/api/news?id=d893f623b55a20d2eb13de2e1f2da21b05fa423da8e2863a1ec199f37fa04adf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.",
                "category": "company",
                "datetime": 1787844720,
                "headline": "Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?"
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141319182,
                "url": "https://finnhub.io/api/news?id=d4f42928d4950efafa33a859d71444523fb97bc758e12a18dd6a9b9bebbba798",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1787657800,
                "headline": "Bristol Myers Spokesperson Says Confirm That We Have Ended Our Partnership With Cellares; Determined Cellares-Partnered Cell Shuttle System Could Not Meet Necessary Requirements To Make Commercial Breyanzi"
              },
              {
                "id": 141316607,
                "url": "https://finnhub.io/api/news?id=f649b9f86ef6cc42c05b0e00dc7665d58e101cc4a89153527c255679d3750e45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/United-States-Treasury-Check-Surrounded-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.",
                "category": "company",
                "datetime": 1787643564,
                "headline": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 140,
            "discarded_article_count": 115
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.3,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.6,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.6,
            "vcp_reason": "跌縮量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 9273351.7,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 11588985.1,
              "avg_vol_20": 9476677.55,
              "avg_vol_30": 9273351.7,
              "range_pct_10": 0.05314798037612444,
              "range_pct_20": 0.10139000817661485,
              "range_pct_30": 0.10793130008176621,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2497083551786352,
              "dist_to_20d_high": 0.10389800703399761,
              "down_shrink_days": 3,
              "breakout_level_20d": 68.24,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4924241655188141
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.1452166802943586,
              "turnoverUsdM": 883.6683767999999,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BMY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 58.5264,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.3,
            "take_profit_price": 64.224,
            "target_multiplier": 1.9,
            "technical_strength": 1.85,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.290433360588717,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 1.3118,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.15
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -128.3
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0728
    },
    "kdj": {
      "d": 12.4,
      "j": 0.71,
      "k": 8.5,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 19.8
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 150055117,
      "recentSlope": -2976638.3,
      "previousSlope": -396390
    },
    "rsi": 12.71,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 65.7051,
      "position": "SAR喺價上",
      "distancePct": 7.45,
      "previousTrend": "下降"
    },
    "ma50": 64.251,
    "macd": {
      "macd": -0.7424874752637862,
      "trend": "看跌",
      "signal": -0.21434935861816523,
      "histogram": -0.5281381166456209
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 64.3371,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.47,
      "score": 6,
      "avgVolume": 9803644,
      "currentVolume": 14450832
    },
    "derived": {
      "ma20": 64.862,
      "ma50": 64.251,
      "prevClose": 62.25,
      "avgVolume10": 12376728,
      "avgVolume20": 9803644,
      "changePercent": -1.77,
      "avgVolumeForScore": 9803644
    },
    "ma_cross": {
      "ma20": 64.862,
      "ma50": 64.251,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 65.2005,
      "prevMa50": 64.167,
      "spreadPct": 0.95,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 60.7598,
      "upper": 68.9642,
      "position": "中間"
    },
    "rsi_short": 7.28,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.47
    }
  }
}

{
  "close": 61.15,
  "volume": 14450832,
  "changePercent": -1.77
}